One-Dose MVA-BN Vaccine Moderately Effective Against Mpox
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 17, 2024 -- One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities, according to a study published online Sept. 11 in The BMJ.
Christine Navarro, M.D., from Public Health Ontario in Toronto, and colleagues estimated the real-world effectiveness of the MVA-BN vaccine against mpox infection in an emulation of a target trial involving 9,803 men with a history of being tested for syphilis and a laboratory-confirmed bacterial sexually transmitted infection in the previous year or who filled a prescription for HIV pre-exposure prophylaxis in the previous year. Those who had been vaccinated 15 days previously were matched with unvaccinated men in a 1:1 ratio on each day between June 12 and Oct. 27, 2022. A total of 3,204 men who received the vaccine were matched with 3,204 unvaccinated controls.
The researchers identified 71 mpox infections, with 0.09 and 0.20 per 1,000 person-days in the vaccinated and unvaccinated groups, respectively, during the study period of 153 days. For one dose of MVA-BN, the estimated vaccine effectiveness against mpox infection was 58 percent.
"Our findings strengthen the evidence that MVA-BN is effective at preventing mpox infection and should be made available and accessible to communities at risk," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
No Link Found Between COVID-19 Vaccination During Pregnancy and Spontaneous Abortion
THURSDAY, May 15, 2025 -- There is no association between COVID-19 vaccination in pregnancy and spontaneous abortion, according to a study published online May 2...
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...
Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.